A myeloperoxidase antibody, usually called MPO-ANCA, is an autoantibody your immune system mistakenly produces against myeloperoxidase, an enzyme normally found inside your own white blood cells. Rather than attacking a foreign invader, this antibody targets a protein your body needs for routine immune defense. When MPO-ANCA circulates in your blood, it can latch onto neutrophils and trigger them to attack the walls of small blood vessels, a process that leads to a group of serious inflammatory diseases collectively known as ANCA-associated vasculitis.
Myeloperoxidase Itself Is a Frontline Immune Weapon
To understand the antibody, you first need to know a bit about the enzyme it targets. Myeloperoxidase (MPO) is a protein found mainly in neutrophils, the most abundant type of white blood cell, and to a lesser extent in monocytes. When neutrophils engulf bacteria, MPO helps kill them by generating hypochlorous acid, essentially a bleach-like chemical, from hydrogen peroxide and chloride ions.1PubMed. Myeloperoxidase: Its role for host defense, inflammation, and neutrophil function This is one of the most potent antimicrobial weapons your body has. MPO can also produce other reactive oxidants from bromide and thiocyanate, broadening its ability to destroy pathogens.2PubMed Central. Myeloperoxidase: Regulation of Neutrophil Function and Target for Therapy
Animal studies show that MPO plays an active role in defending against blood infections. Neutrophils use the MPO system to produce bactericidal halogenating chemicals during sepsis, confirming that the enzyme is not just a lab curiosity but a genuine protector against life-threatening infections.3PubMed. Neutrophils employ the myeloperoxidase system to generate antimicrobial brominating and chlorinating oxidants during sepsis The downside is that these same powerful oxidants can damage your own tissues. Hypochlorous acid generated by MPO can create covalent bonds between DNA and proteins, which may contribute to tissue injury in areas of intense inflammation.4PubMed. Hypochlorous acid produced by the myeloperoxidase system of human phagocytes induces covalent cross-links between DNA and protein In other words, MPO is both essential for immune defense and capable of collateral harm when it ends up in the wrong place or is activated at the wrong time.
How the Immune System Turns Against MPO
Under normal circumstances, your immune system recognizes MPO as part of “self” and leaves it alone. In people who develop MPO-ANCA, that tolerance breaks down. The immune system starts manufacturing antibodies that bind to MPO, treating it as if it were a foreign threat. The exact trigger for this breakdown is not fully understood, but certain environmental and drug exposures can set the process in motion.
Hydralazine, a blood-pressure medication, is one of the best-documented drug triggers. Patients on hydralazine sometimes develop sharply elevated MPO-ANCA levels along with kidney and vascular inflammation.5PubMed Central. Hydralazine-Induced Vasculitis Recent research has shown that hydralazine can chemically modify the MPO protein itself, creating new molecular structures that the immune system no longer recognizes as self.6PubMed Central. Sequential carbonyl derivatives and hydrazone adduct formation on myeloperoxidase contribute to development of ANCA vasculitis Other medications, including certain thyroid drugs and the antibiotic minocycline, have also been implicated, though less frequently.
Environmental exposures matter too. Long-term silica exposure, which often occurs in mining, construction, and sandblasting, has been linked to ANCA production, although silica exposure without established silicosis was not on its own associated with ANCA positivity in one study.7PubMed. Exposure to silica and risk of ANCA-associated vasculitis The picture that emerges is one of a multi-hit process: genetic susceptibility, environmental exposure, and possibly infection combine to erode immune tolerance to MPO.
What MPO-ANCA Actually Does to Blood Vessels
Once MPO-ANCA antibodies are circulating, they don’t just float around harmlessly. When neutrophils are primed by inflammatory signals like tumor necrosis factor, they push small amounts of MPO to their outer surface. MPO-ANCA binds to this surface-exposed MPO and, through the antibody’s tail region (the Fc portion), triggers the neutrophil into a full activation state. This produces a burst of toxic oxygen radicals and the release of destructive enzymes directly onto the blood vessel wall.8PubMed Central. The activation of the neutrophil respiratory burst by anti-neutrophil cytoplasm autoantibody (ANCA) from patients with systemic vasculitis requires tyrosine kinases and protein kinase C activation Experiments with neutrophils that lack MPO have confirmed that the enzyme must be present on the cell surface for MPO-ANCA to activate the neutrophil; remove the target and the antibody loses its ability to cause harm.9PubMed. Expression of myeloperoxidase (MPO) by neutrophils is necessary for their activation by anti-neutrophil cytoplasm autoantibodies (ANCA) against MPO
The damage doesn’t stop with one round of activation. Activated neutrophils get stuck in the tiny blood vessels of organs like the kidneys and lungs, where they undergo a dramatic form of cell death called NETosis. During this process, the neutrophil ejects its DNA and internal proteins, including MPO, into the surrounding tissue. This material both injures the vessel wall and deposits fresh MPO in the tissue, which can be recognized by more antibodies, attracting more neutrophils and perpetuating the cycle.10PubMed Central. Neutrophil Extracellular Traps: A Potential Therapeutic Target in MPO-ANCA Associated Vasculitis? The complement system (another arm of immunity) also joins in, amplifying the inflammation.11PubMed Central. Mechanisms of vascular damage in ANCA vasculitis The result is a self-sustaining loop of immune attack that, left untreated, progressively destroys small blood vessels and the organs they supply.
MPO-ANCA also influences immune cells beyond neutrophils. When researchers exposed monocytes to anti-MPO antibodies, the monocytes released less of the inflammatory signals IL-10 and IL-6 in response to bacterial components, and these changes depended on the antibody interacting with Fc receptors and on active MPO enzyme. The antibodies also promoted monocyte survival and their maturation into macrophages by boosting production of a growth factor called CSF-1.12PubMed Central. Anti-myeloperoxidase antibodies attenuate the monocyte response to LPS and shape macrophage development This suggests MPO-ANCA reshapes broader immune behavior, not just neutrophil attacks on vessel walls.
The Diseases Linked to MPO-ANCA
MPO-ANCA is most strongly associated with two forms of ANCA-associated vasculitis: microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA, formerly called Churg-Strauss syndrome). A smaller proportion of patients with granulomatosis with polyangiitis (GPA, formerly Wegener’s) also test positive for MPO-ANCA, though GPA is more commonly linked to antibodies against a different enzyme called proteinase 3 (PR3-ANCA).13PubMed Central. ANCA Glomerulonephritis and Vasculitis
Microscopic polyangiitis tends to strike the kidneys first and hardest. Kidney inflammation with blood or protein in the urine appears in roughly 80% of patients, and rapidly progressive glomerulonephritis (where kidney function deteriorates over days to weeks) is reported in up to 80–100% of those with renal involvement. Weight loss shows up in over 70%, skin rashes in over 60%, and nerve damage in a similar proportion.14PubMed Central. Microscopic polyangiitis: an incidental finding in a patient with stroke In children with MPA, the constellation can be similar: one series found hematuria with proteinuria and purpura in every case, with more than half developing a combined lung-kidney syndrome.15PubMed. Childhood microscopic polyangiitis associated with MPO-ANCA
In EGPA, the antibody’s presence changes the clinical picture. A Chinese cohort study found that patients with positive MPO-ANCA had higher overall disease activity and higher rates of kidney involvement, biopsy-proven vasculitis, fever, and muscle pain compared with ANCA-negative EGPA patients. Conversely, those who were ANCA-negative more often developed cardiac involvement and severe asthma.16PubMed Central. Clinical Significance of MPO-ANCA in Eosinophilic Granulomatosis With Polyangiitis: Experience From a Longitudinal Chinese Cohort Knowing whether a patient’s ANCA is positive or negative therefore shapes expectations about which organs are at greatest risk.
Why the Kidneys and Lungs Bear the Brunt
The kidney is a common battleground because its glomeruli contain a dense network of tiny blood vessels, exactly the kind of small-vessel bed that ANCA-activated neutrophils tend to lodge in. The hallmark kidney lesion is pauci-immune necrotizing and crescentic glomerulonephritis, where the glomeruli show tissue death and crescent-shaped scars but very little antibody deposition on biopsy, distinguishing it from other forms of kidney inflammation.13PubMed Central. ANCA Glomerulonephritis and Vasculitis When MPO-ANCA levels persist or reappear after treatment, the outlook for the kidneys worsens: patients with ongoing MPO-ANCA positivity have a lower chance of kidney recovery and a higher risk of kidney failure.17PubMed. Association between kinetic of anti-neutrophil cytoplasmic antibody (ANCA), renal survival and relapse risk in ANCA glomerulonephritis
The lungs have their own pattern. Interstitial lung disease, including pulmonary fibrosis, is strongly linked to MPO-ANCA and MPA specifically, rather than to PR3-ANCA or GPA. Pulmonary fibrosis can be present in up to 45% of MPA patients, and cases of ILD associated with PR3-ANCA have only rarely been reported.18European Respiratory Review. Antineutrophil cytoplasmic antibody-associated interstitial lung disease: a review In some cases, the lung scarring shows up before any other sign of vasculitis. Patients initially diagnosed with ordinary pulmonary fibrosis sometimes later convert to ANCA-positive status and go on to develop full systemic vasculitis.19PubMed Central. Interstitial Lung Disease with ANCA-associated Vasculitis When lung disease coexists with vasculitis in other organs, symptoms can broaden to include alveolar hemorrhage (coughing up blood), fever, weight loss, and signs of inflammation in the kidneys, skin, nerves, and joints.20European Journal of Internal Medicine. What Is a Myeloperoxidase Antibody & What Does It Do? – Section: 4.1 Clinical manifestations and biomarkers
How MPO-ANCA Is Detected
For decades, the first-line test for ANCA was indirect immunofluorescence (IIF), where patient serum is applied to a slide of fixed neutrophils and the fluorescence pattern is read under a microscope. MPO-ANCA typically produces a “perinuclear” (P-ANCA) pattern, with fluorescence concentrated around the nucleus, though rare exceptions exist where MPO-ANCA creates a misleading cytoplasmic pattern usually associated with PR3-ANCA.21PubMed Central. Myeloperoxidase-antineutrophil Cytoplasmic Antibodies with Cytoplasmic Fluorescence Pattern Modern practice has shifted toward antigen-specific immunoassays that directly measure antibodies against MPO protein, providing more consistent results. A recent comparison of detection methods in a predominantly MPO-ANCA cohort found that chemiluminescent enzyme immunoassays and fluorescent enzyme immunoassays had sensitivities in the low 90s with specificities in the mid-90s, while older ELISA methods achieved about 86% sensitivity with 98% specificity.22PubMed. Comparison of different ANCA detection methods in a predominantly MPO-ANCA-associated vasculitis cohort International guidelines now recommend starting with antigen-specific immunoassays rather than immunofluorescence screening, a shift that reflects the improved standardization and accuracy of modern tests.23PubMed Central. History of antineutrophil cytoplasmic autoantibodies: Milestones in rheumatology
One practical caveat: a positive MPO-ANCA result does not automatically mean a person has vasculitis. Low-level positivity can show up with certain infections, other autoimmune conditions, and some cancers. Infective endocarditis, for example, can trigger ANCA positivity that sometimes presents as a double-positive result (both PR3 and MPO), accompanied by other autoantibodies. Mistaking endocarditis for ANCA vasculitis and treating it with immunosuppression rather than antibiotics would be dangerous.24PubMed Central. Infective endocarditis mimicking ANCA-associated vasculitis: does it require immunosuppressive therapy? A case report and literature review This is why clinicians interpret MPO-ANCA results in the full clinical context, not as a standalone diagnostic answer.
Tracking MPO-ANCA Levels Over Time
Beyond diagnosis, MPO-ANCA levels carry prognostic weight. In vasculitis patients with kidney involvement, those whose MPO-ANCA levels became persistently negative after treatment essentially did not relapse. In contrast, patients whose antibodies reappeared had roughly double the risk of relapse.25PubMed Central. Maintenance of Remission and Risk of Relapse in Myeloperoxidase-Positive ANCA-Associated Vasculitis with Kidney Involvement There is an important nuance here compared with PR3-ANCA. In that same body of data, persistent or recurrent PR3-ANCA was more strongly associated with disease relapse, while persistent or recurrent MPO-ANCA had a tighter link to kidney failure and poor renal recovery.17PubMed. Association between kinetic of anti-neutrophil cytoplasmic antibody (ANCA), renal survival and relapse risk in ANCA glomerulonephritis So for MPO-ANCA patients, serial lab monitoring serves a dual purpose: it tracks the risk of a flare and the risk of progressive kidney damage.
How frequently doctors check ANCA levels varies by practice, but many rheumatologists and nephrologists retest every few months during the first couple of years after treatment, spacing out monitoring once a patient has been stably in remission with undetectable antibodies. A rising titer does not always mean a relapse is imminent, but it does raise the alarm and may prompt closer surveillance or preemptive treatment adjustments.
Treatment Landscape
Standard treatment for MPO-ANCA vasculitis involves induction therapy to halt active disease, followed by maintenance therapy to prevent relapse. Induction typically combines high-dose glucocorticoids with either cyclophosphamide or rituximab. The goal during induction is to rapidly suppress neutrophil activation and halt the vessel-wall destruction. Maintenance often uses rituximab, azathioprine, or mycophenolate to keep the immune system quiet long-term.
A newer option, avacopan, blocks a complement receptor (C5aR) to dampen inflammation without the heavy side effects of prolonged steroid use. In a randomized trial, about 71% of patients on avacopan achieved sustained remission at one year compared with about 56% on a standard steroid taper, and the avacopan group showed better kidney function recovery and less steroid-related toxicity.26PubMed Central. Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial This drug’s approval represented a meaningful step toward steroid-sparing regimens, an area where patients and clinicians alike have been pushing for progress, because long-term steroid use brings its own burden of bone loss, diabetes, infection risk, and weight gain.
When MPO-ANCA vasculitis is drug-induced, such as from hydralazine, stopping the offending medication is the first step. Many drug-induced cases improve substantially once the drug is withdrawn, though some still require a course of immunosuppression if organ damage is already underway.
MPO-ANCA Outside of Vasculitis
While vasculitis is the headline association, MPO-ANCA can show up in other autoimmune conditions. In rheumatoid arthritis, anti-MPO antibodies have been found in a subset of patients, and their presence correlated with nodular disease, more active joints, and pulmonary fibrosis.27Annals of the Rheumatic Diseases. Anti-myeloperoxidase antibodies in patients with rheumatoid arthritis: prevalence, clinical correlates, and IgG subclass This observation raises the question of whether MPO-ANCA in RA patients is simply a marker of more aggressive autoimmunity or whether it actively contributes to extra-articular complications like lung scarring.
Independent of the antibody itself, the MPO enzyme has drawn attention in cardiovascular risk. In rheumatoid arthritis, MPO damages high-density lipoprotein (HDL, the “good cholesterol”) through oxidation, reducing its ability to remove cholesterol from blood vessel walls.28PubMed Central. High density lipoprotein is targeted for oxidation by myeloperoxidase in rheumatoid arthritis Elevated MPO levels have also been identified as a predictor of cardiovascular risk in RA patients, alongside traditional markers like C-reactive protein.29PubMed. Myeloperoxidase as an important predictor of cardiovascular risk in individuals with rheumatoid arthritis Whether measuring MPO or MPO-ANCA will ever become part of routine cardiovascular screening remains to be seen, but the link between MPO activity and atherosclerosis has been a productive area of research for the past two decades.
Rare Overlaps and Diagnostic Traps
Occasionally MPO-ANCA appears in unexpected clinical settings. A case report documented a 72-year-old man who presented with kidney failure, severe anemia, and positive MPO-ANCA, only for a bone marrow biopsy to reveal multiple myeloma as the underlying driver. The vasculitis and the blood cancer coexisted, complicating both diagnosis and treatment.30European Journal of Inflammation. Multiple Myeloma Presenting as MPO-ANCA Associated Microscopic Polyangiitis Stories like these are rare but illustrate why a positive MPO-ANCA result always demands a thorough workup. The antibody is a clue, not a final diagnosis.
Infections pose another diagnostic trap. Bacterial endocarditis, tuberculosis, and certain chronic infections can provoke transient ANCA production, sometimes with features that closely mimic true vasculitis, including kidney lesions and skin changes. In endocarditis specifically, the ANCA profile can be atypical: double-positive for both PR3 and MPO, with additional autoantibodies in tow.24PubMed Central. Infective endocarditis mimicking ANCA-associated vasculitis: does it require immunosuppressive therapy? A case report and literature review Giving immunosuppressive drugs to someone whose real problem is an active infection can be catastrophic, so sorting out infection-driven ANCA from autoimmune vasculitis is one of the highest-stakes diagnostic decisions in this field. Blood cultures, echocardiography, and careful clinical history usually settle the question, but the overlap is close enough to give experienced clinicians pause.